Erratum to: Calcium/Calmodulin-Dependent Protein Kinase II and Eukaryotic Elongation Factor 2 Kinase Pathways Mediate the Antidepressant Action of Ketamine.

Biol Psychiatry July 14, 2026 correction DOI: 10.1016/j.biopsych.2026.06.020 (opens in new tab) via PubMed

Summary

AI-generated from the abstract

This erratum corrects errors in the original article about the roles of calcium/calmodulin-dependent protein kinase II and eukaryotic elongation factor 2 kinase pathways in mediating the antidepressant effects of ketamine.

Abstract

Erratum to: Calcium/Calmodulin-Dependent Protein Kinase II and Eukaryotic Elongation Factor 2 Kinase Pathways Mediate the Antidepressant Action of Ketamine.

Correction. Ketamine vs Electroconvulsive Therapy in the Management of Treatment-Resistant Depression: Do We Need More Data? The Journal of Clinical Psychiatry February 11, 2025 via PubMed
Corrigendum to "Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study". Ther Adv Psychopharmacol May 19, 2026 via PubMed Central
Corrigendum: A cohort-based case report: The impact of ketamine-assisted therapy embedded in a community of practice framework for healthcare providers with PTSD and depression. Frontiers in Psychiatry January 1, 2022 via PubMed
Extending ketamine's antidepressant effects. Science (New York, N.Y.) May 8, 2025 9 citations via PubMed
Enhanced ERK activity extends ketamine's antidepressant effects by augmenting synaptic plasticity. Science (New York, N.Y.) May 8, 2025 44 citations via PubMed

Comments

No comments yet.

Summary

Abstract

Related reading

Comments